Bronchogen's tripeptide sibling. Preclinical only. Often mislabeled as a gut peptide.
What is it? A synthetic tripeptide Glu-Asp-Gly (EDG), ~319 Da. Khavinson's respiratory-epithelium bioregulator, positioned alongside the tetrapeptide Bronchogen (AEDL). Name from Greek chonchos for cartilaginous/respiratory structures.
What does it do? Khavinson's epigenetic-bioregulator model proposes EDG engaging chromatin targets in bronchial epithelial cells. Preclinical cell-culture work reports effects on differentiation markers, tight-junction and mucociliary-machinery genes, and antioxidant enzyme expression.
Does the evidence hold up? Preclinical only. Cell-culture and aged-animal work from the Khavinson lab. Zero randomized controlled human trials. Zero pulmonology guideline recognition. Zero regulatory filings.
Who uses it? Longevity circles combining the Khavinson respiratory pair (Chonluten plus Bronchogen). 10–20 day oral or injectable cycles, 2–3 times a year. Not a bronchodilator, not an asthma or COPD drug.
Bottom line? Bronchogen's smaller sibling. Same Khavinson lab. Same empty human-trial shelf.
Chonluten is a synthetic short peptide within the Khavinson bioregulator program. Its sequence is Glu-Asp-Gly (EDG), a tripeptide with an approximate molecular weight of 319 daltons. Within the Khavinson framework, EDG is positioned as a respiratory-epithelium-directed bioregulator — a companion peptide to the tetrapeptide Bronchogen (AEDL). The two are sometimes used together in bronchial-support community protocols, despite sharing the respiratory-tissue target.
Historically, the Khavinson program has a tradition of identifying multiple short peptides per tissue — with slightly different chain lengths and residue compositions — and claiming complementary tissue-directed activity. Chonluten (EDG) is the Khavinson tripeptide in this respiratory-bioregulator subgroup.
Note: Some community references and older Kalios content describe Chonluten as a gastrointestinal-mucosal bioregulator. The primary Khavinson-group literature and current vendor taxonomy position EDG as a bronchial-mucosal/respiratory peptide; the GI-mucosa framing derives in part from the broader "mucosal epithelium" framing of the Khavinson program and the mechanistic overlap between respiratory and GI mucosal tissue biology. Users should be aware that the mucosal-tissue targeting is ambiguous across sources.
The biology of mucosal epithelium is informative context. The human airway epithelium is a complex pseudostratified columnar sheet comprising basal cells (progenitors), ciliated cells (mucociliary clearance), goblet cells (mucin secretion), and club cells (secretory defense). Tight-junction and adherens-junction complexes maintain the selective barrier that separates inhaled air — with its pollutants, pathogens, and allergens — from the sub-epithelial immune system. Dysfunction of this barrier is implicated in asthma, COPD, bronchiectasis, chronic rhinosinusitis, and respiratory long-COVID. Similarly, the gastrointestinal epithelial barrier, with its own tight-junction machinery and mucin layer, is implicated in IBD, celiac disease, and various systemic inflammatory conditions under the broad heading of "intestinal permeability" or "leaky gut." Against this backdrop, a short peptide that reportedly supports tight-junction assembly and barrier integrity would, in principle, be of interest — but the gap between "in principle interesting preclinical activity" and "clinically validated therapy" is exactly what the Chonluten evidence base does not bridge.
Commercially, Chonluten is distributed as an oral capsule within the Khavinson Revilab / NPCRiZ dietary-supplement line and as a lyophilized research peptide (typically 20 mg vials) for subcutaneous or intramuscular research use. Neither form is a registered pharmaceutical. In Russia it is sold as a BAD; outside Russia it is research-only. In the Western optimization community, Chonluten occupies a very small niche among Khavinson-protocol users interested in respiratory or mucosal support. It is not used or recognized by mainstream pulmonology or gastroenterology.
The Khavinson framework proposes that short bioregulator peptides act as sequence-specific DNA-binding molecules modulating promoter activity at tissue-specific gene sets. Chonluten's mechanism is described within this epigenetic-bioregulator framework. Independent mechanism validation outside the originating program is limited.
Limitation: as with all Khavinson bioregulators, mechanism is primarily a hypothesis developed within one research program, and structure-resolution validation (DNA-binding footprints, ChIP-seq replication, prospective gene-target mapping) is not available at the level expected for rigorous sequence-specific DNA binders.
Chonluten's published literature is concentrated in Khavinson-program publications in Russian and Springer-indexed English journals. Evidence is preclinical. No randomized controlled human trials.
Chonluten's evidence base is preclinical, dominated by a single research program, not independently replicated by Western groups. No randomized controlled human trials exist. Mainstream respiratory and GI medicine does not recognize Chonluten as a therapeutic. Substituting Chonluten for evidence-based respiratory or GI care is inappropriate. Claims that Chonluten "treats" asthma, COPD, chronic gastritis, or IBD are unsupported.
Synthetic Chonluten (EDG) has not been evaluated in published randomized controlled human trials. Accessible human-use information:
As with Cartalax and other Khavinson short peptides, the absence of human RCT data is the central evidentiary fact. The Khavinson-framework scientific case rests on preclinical mechanism demonstrations (cell culture, aged-animal models) and an epigenetic-bioregulator hypothesis. The translation from those data to clinical benefit in any human respiratory or gastrointestinal disease is unvalidated. Users who have found observational, clinical, or self-experimentation benefit cannot rule out placebo, concurrent standard-of-care, or regression-to-mean effects.
To the extent Chonluten has a biologically coherent positioning, it sits within the broader framework of the common mucosal immune system — the recognition that respiratory, gastrointestinal, genitourinary, and ocular mucosal surfaces share developmental origin, secretory IgA / IgM machinery, and tolerogenic/immunoregulatory circuits. A peptide with even modest effects on epithelial differentiation, tight-junction protein expression, or mucin-gene activity could in principle have cross-compartment effects. This framing is more mainstream than some other aspects of the Khavinson program and is consistent with the broader literature on secretory-IgA physiology, gut-lung axis, mucosal dendritic cell cross-compartment trafficking, and microbiota-immunity interactions.
The practical limitation, however, is that "could in principle" and "demonstrated to do so" are different claims. No published study documents Chonluten-induced changes in secretory IgA output, tight-junction protein abundance on human biopsy, transepithelial electrical resistance in organoid models from primary human tissue, or common-mucosal-system functional endpoints. The Khavinson-program cell-culture data are interesting but not sufficient to establish that AEDL or EDG cross-modulate the common mucosal system in humans.
This matters for users evaluating Chonluten for ambiguous respiratory + GI concerns. A user with chronic sinus issues, recurrent respiratory infections, and atypical GI symptoms is not well-served by a compound whose mucosal-immune effects are mechanistically plausible but experimentally unverified in human tissue. Evidence-based workup — allergy testing, immune panel if indicated, GI evaluation per gastroenterology, pulmonology referral where chronic lower-airway symptoms persist — remains the first-line posture.
No clinical-trial-derived human dose exists. Doses below summarize the Khavinson protocol framework and community practice. Not FDA-approved prescribing.
| Form | Typical Dose | Frequency | Cycle / Notes |
|---|---|---|---|
| Oral capsule (Khavinson BAD — Revilab / NPCRiZ) | 200–400 μg | 1–2× daily | Microdose oral capsule. 10–20 day course, 2–3 courses per year per protocol. |
| Oral lyophilized research peptide | 5–10 mg | Once daily | Community use of injectable-grade peptide orally/sublingually. Order(s)-of-magnitude higher than BAD capsule; bioavailability poorly characterized. |
| Subcutaneous / IM injection | 100–200 μg | Once daily | Community injectable protocols, 10–20 day courses. |
| Course length | 10–20 days | — | Standard Khavinson bioregulator cycle. |
| Cycle frequency | 2–3 courses per year | — | Seasonal or elective timing. |
Large dosage gap between the Khavinson BAD microdose and the research-peptide community oral dose, with no validated human PK study. Community dosing is not clinically validated. Self-administration of research peptides for respiratory or GI conditions is not a substitute for evidence-based care. Consult a licensed clinician.
Research-peptide Chonluten is supplied lyophilized, typically in 10 mg or 20 mg vials. Oral BAD capsules are pre-formulated.
| Vial | BAC Water | Concentration | 100 μg Dose | 200 μg Dose |
|---|---|---|---|---|
| 10 mg | 2 mL | 5 mg/mL (5,000 μg/mL) | 2 units (0.02 mL) | 4 units (0.04 mL) |
| 10 mg | 5 mL | 2 mg/mL (2,000 μg/mL) | 5 units (0.05 mL) | 10 units (0.10 mL) |
| 20 mg | 2 mL | 10 mg/mL (10,000 μg/mL) | 1 unit (0.01 mL) | 2 units (0.02 mL) |
| 20 mg | 5 mL | 4 mg/mL (4,000 μg/mL) | 2.5 units (0.025 mL) | 5 units (0.05 mL) |
Bronchogen (AEDL, tetrapeptide) and Chonluten (EDG, tripeptide) are both positioned within the Khavinson respiratory-epithelium-directed bioregulator subgroup. Community protocols often pair them during respiratory-support cycles. No clinical validation of the combination.
BPC-157 has preclinical data for GI mucosal healing through angiogenesis and anti-inflammatory pathways. Community combinations pair BPC-157 with Chonluten for broader mucosal-repair protocols. Not clinically validated.
Khavinson thymic peptides are often co-cycled with tissue-specific bioregulators. Mechanistically complementary.
LL-37 is a cathelicidin antimicrobial peptide with direct antimicrobial and mucosal-defense effects. Mechanistically distinct companion for respiratory-infection-focused protocols.
Commonly included in broader Khavinson longevity stacks.
Chonluten is not approved by the U.S. FDA for any indication and has not been the subject of an IND or NDA filing. It is not approved by the European Medicines Agency.
In Russia, Chonluten is sold as a "biologically active additive" (BAD — dietary supplement) through Khavinson-affiliated distributors (NPCRiZ, Revilab). It is not a registered pharmaceutical.
Chonluten is not on the FDA Category 2 Bulk Drug Substances list, and it is not among the peptides under HHS Secretary Robert F. Kennedy Jr.'s February 2026 Category 2 reclassification announcement.
Chonluten is not specifically named on the WADA Prohibited List. Athletes should consult their sport-specific federation.
No pulmonology or gastroenterology specialty society (ATS, ERS, GOLD, AGA, ACG) recognizes Chonluten as a therapeutic.
Chonluten is not approved for human use in the United States. The oral BAD form is distributed internationally through Khavinson-affiliated channels; the injectable lyophilized peptide is available through research-chemical suppliers for laboratory research use only. Personal-use import to the U.S. occupies a legal gray zone; bulk import is enforced against.
No U.S. compounding pharmacy can legally compound Chonluten — it has no FDA-approved reference product and is not on the Category 1 bulk substance list. Purity verification via third-party HPLC + MS COA is the practical quality floor.
Chonluten is not among the peptides under HHS Secretary Robert F. Kennedy Jr.'s February 2026 Category 2 reclassification announcement. Absent formal FDA development, it will remain unavailable through legitimate U.S. clinical channels.
Access and availability information as of April 2026. Kalios does not sell compounds.
People researching Chonluten often also look at these:
Khavinson tripeptide (Glu-Asp-Leu). Hepatic/immune short-peptide bioregulator.
Khavinson tetrapeptide (Lys-Glu-Asp-Trp). Pancreas-oriented bioregulator.
Khavinson tripeptide (Ala-Glu-Asp). Cartilage and joint-oriented short peptide bioregulator.
Khavinson tripeptide (Ala-Glu-Asp). Heart-tissue-oriented bioregulator.
Last updated: April 2026 | Profile authored by Kalios Peptides research team